Charles A. Leath - Concepedia

Author

Charles A. Leath

University of Alabama at Birmingham ORCID

Also Known As

C A Leath, C LEATH, C Leath, C Leath III, C Leath Iii, C. A. Leath, C. A. Leath Iii, C. Leath, C. Leath III, C.A. LEATH

416

Publications

8.3K

Citations

H-Index

111

Concepts

All Affiliations

University of Alabama at Birmingham Memorial Sloan Kettering Cancer Center Brooke Army Medical Center University of Oklahoma Health Sciences Center Duke Medical Center

About

Charles A. Leath is an author at University of Alabama at Birmingham specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	64	3.7K
2	Public Health	13	17	518
3	Health Sciences	8	8	627
4	Engineering	1	1	14
5	Nursing	1	1	31

Charles A. Leath

103

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer Robert L. Coleman, Gini F. Fleming, Mark F. Brady, New England Journal of Medicine	2019	886
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, Journal of the National Comprehensive Cancer Network Surgical OncologyEpithelial Ovarian CancerCancer ManagementPelvic Reconstructive SurgeryGynecology	2021	688
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, New England Journal of Medicine	2023	626
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022 Deborah K. Armstrong, Ronald D. Alvarez, Floor Backes, Journal of the National Comprehensive Cancer Network Nccn Guidelines® InsightsTumoral PathologyEndocrine-related CancerEpithelial Ovarian CancerMedicine	2022	369
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study Robert L. Coleman, Domenica Lorusso, Christine Gennigens, The Lancet Oncology Tisotumab VedotinCervical CancerMetastatic Cervical CancerMedicineClinical Trials	2021	367
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019 Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, Journal of the National Comprehensive Cancer Network	2019	323
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study Ana Oaknin, Lucy Gilbert, Anna V. Tinker, Journal for ImmunoTherapy of Cancer	2022	300
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial Richard T. Penson, Ricardo Villalobos-Valencia, David Cibula, Journal of Clinical Oncology	2020	287
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer Beth Y. Karlan, Amit M. Oza, Gary Richardson, Journal of Clinical Oncology	2011	225
A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer Caroline W. Cohen, Kevin R. Fontaine, Rebecca C. Arend, Journal of Nutrition ObesityMetabolic SyndromeNutritionSerum InsulinWestern Pattern Diet	2018	151

Page 1